Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
PT-141 (Bremelanotide) (PT141) is a tanning peptide, at the fda approved stage in the published literature. Metabolite of Melanotan II developed specifically for sexual dysfunction. FDA approved as Vyleesi for hypoactive sexual desire disorder.
Metabolite of Melanotan II developed specifically for sexual dysfunction. FDA approved as Vyleesi for hypoactive sexual desire disorder.
| Research Status | FDA approved |
|---|---|
| Half-Life | 2-4 hours |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 1.75 mg as needed |
MC3R and MC4R agonist that acts centrally to increase sexual desire without direct vascular effects.
Metabolite of Melanotan II developed specifically for sexual dysfunction. FDA approved as Vyleesi for hypoactive sexual desire disorder.
MC3R and MC4R agonist that acts centrally to increase sexual desire without direct vascular effects.
PT-141 (Bremelanotide) is at the following stage in the published literature: FDA approved. All information is for research and educational purposes only.
Reported half-life: 2-4 hours.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.